Célia Duarte Cruz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1879513/publications.pdf Version: 2024-02-01



<u>CÃΩLIA DUADTE COUZ</u>

#	Article	IF	CITATIONS
1	Rewired glycosylation activity promotes scarless regeneration and functional recovery in spiny mice after complete spinal cord transection. Developmental Cell, 2022, 57, 440-450.e7.	7.0	26
2	Biomarkers for Bladder Pain Syndrome/Interstitial Cystitis. Current Bladder Dysfunction Reports, 2021, 16, 12-18.	0.5	3
3	The urethra in continence and sensation: Neural aspects of urethral function. Neurourology and Urodynamics, 2021, 40, 744-752.	1.5	3
4	TASCl—transcutaneous tibial nerve stimulation in patients with acute spinal cord injury to prevent neurogenic detrusor overactivity: protocol for a nationwide, randomised, sham-controlled, double-blind clinical trial. BMJ Open, 2020, 10, e039164.	1.9	18
5	Chronic Pain After Spinal Cord Injury: Is There a Role for Neuron-Immune Dysregulation?. Frontiers in Physiology, 2020, 11, 748.	2.8	20
6	Peripherally administered melanocortins induce mice fat browning and prevent obesity. International Journal of Obesity, 2019, 43, 1058-1069.	3.4	9
7	Underactive bladder in aging rats is associated with a reduced number of serotoninâ€expressing cells in the urethra and is improved by serotonin application to the urethra. LUTS: Lower Urinary Tract Symptoms, 2019, 11, 248-254.	1.3	9
8	Effects of early intravesical administration of resiniferatoxin to spinal cordâ€injured rats in neurogenic detrusor overactivity. Neurourology and Urodynamics, 2019, 38, 1540-1550.	1.5	11
9	Partners in Crime: NGF and BDNF in Visceral Dysfunction. Current Neuropharmacology, 2019, 17, 1021-1038.	2.9	29
10	Evidence for an urethroâ€vesical crosstalk mediated by serotonin. Neurourology and Urodynamics, 2018, 37, 2389-2397.	1.5	14
11	Author Reply. Urology, 2017, 99, 55-56.	1.0	0
12	MP42-06 EXPRESSION AND FUNCTION OF SEROTONIN PARANEURONAL CELLS IN THE URETHRAL EPITHELIUM OF HUMAN AND RODENTS. Journal of Urology, 2017, 197, .	0.4	0
13	Urinary Neurotrophin Levels Increase in Women With Stress Urinary Incontinence After a Midurethral Sling Procedure. Urology, 2017, 99, 49-56.	1.0	7
14	Impairment of sensory afferents by intrathecal administration of botulinum toxin A improves neurogenic detrusor overactivity in chronic spinal cord injured rats. Experimental Neurology, 2016, 285, 159-166.	4.1	22
15	The Role of Brain-Derived Neurotrophic Factor (BDNF) in the Development of Neurogenic Detrusor Overactivity (NDO). Journal of Neuroscience, 2015, 35, 2146-2160.	3.6	38
16	Coâ€administration of transient receptor potential vanilloid 4 (<scp>TRPV4</scp>) and <scp>TRPV1</scp> antagonists potentiate the effect of each drug in a rat model of cystitis. BJU International, 2015, 115, 452-460.	2.5	26
17	Can the adrenergic system be implicated in the pathophysiology of bladder pain syndrome/interstitial cystitis? A clinical and experimental study. Neurourology and Urodynamics, 2015, 34, 489-496.	1.5	31
18	Urinary bladder inflammation induces changes in urothelial nerve growth factor and <scp>TRPV</scp> 1 channels. British Journal of Pharmacology, 2015, 172, 1691-1699.	5.4	32

CéLIA DUARTE CRUZ

#	Article	IF	CITATIONS
19	Biomarkers of spinal cord injury and ensuing bladder dysfunction. Advanced Drug Delivery Reviews, 2015, 82-83, 153-159.	13.7	31
20	Intrathecal administration of botulinum toxin type <scp>A</scp> improves urinary bladder function and reduces pain in rats with cystitis. European Journal of Pain, 2014, 18, 1480-1489.	2.8	36
21	Biomarkers in lower urinary tract symptoms/overactive bladder. Current Opinion in Urology, 2014, 24, 352-357.	1.8	25
22	MP76-06 URINARY NEUROTROPHINS AND QMAX VARIATION MAY PREDICT DE NOVO URGENCY IN SUI PATIENTS AFTER A MIDURETHRAL SLING (MUS) SURGERY. Journal of Urology, 2014, 191, .	0.4	1
23	Neurotrophins in bladder function: What do we know and where do we go from here?. Neurourology and Urodynamics, 2014, 33, 39-45.	1.5	58
24	Ulcerative and Nonulcerative Forms of Bladder Pain Syndrome/Interstitial Cystitis Do Not Differ in Symptom Intensity or Response to Onabotulinum Toxin A. Urology, 2014, 83, 1030-1034.	1.0	50
25	Brain-derived neurotrophic factor, acting at the spinal cord level, participates in bladder hyperactivity and referred pain during chronic bladder inflammation. Neuroscience, 2013, 234, 88-102.	2.3	24
26	Transient receptor potential channels in bladder function. Acta Physiologica, 2013, 207, 110-122.	3.8	39
27	Urinary Neurotrophic Factors in Healthy Individuals and Patients with Overactive Bladder. Journal of Urology, 2013, 189, 359-365.	0.4	68
28	Animal Models of Cystitis. Methods in Pharmacology and Toxicology, 2012, , 397-409.	0.2	0
29	Effect of OnabotulinumtoxinA on Intramural Parasympathetic Ganglia: An Experimental Study in the Guinea Pig Bladder. Journal of Urology, 2012, 187, 1121-1126.	0.4	30
30	817 URINARY NEUROTROPHIC FACTORS IN BLADDER PAIN SYNDROME/INTERSTITIAL CYSTITIS. Journal of Urology, 2012, 187, .	0.4	1
31	1968 THE ROLE OF URINARY NEUROTROPHIC FACTORS IN OVERACTIVE BLADDER SYNDROME. Journal of Urology, 2012, 187, .	0.4	0
32	Rat detrusor overactivity induced by chronic spinalization can be abolished by a transient receptor potential vanilloid 1 (TRPV1) antagonist. Autonomic Neuroscience: Basic and Clinical, 2012, 166, 35-38.	2.8	31
33	Neurotrophins as regulators of urinary bladder function. Nature Reviews Urology, 2012, 9, 628-637.	3.8	78
34	365 TRPV1 and TRPV4 antagonists have synergistic effect for treating bladder overactivity in rats. European Urology Supplements, 2012, 11, e365.	0.1	5
35	366 TRPV1 and TRPV4 expression in bladder neurons during normal condition and during cystitis. European Urology Supplements, 2012, 11, e366.	0.1	1
36	993 High urinary levels of nerve growth factor and brain-derived neurotrophic factor in women with overactive bladder syndrome normalize after lifestyle intervention and antimuscarinic therapy. European Urology Supplements, 2012, 11, e993-e993a.	0.1	1

CéLIA DUARTE CRUZ

#	Article	IF	CITATIONS
37	Spread of OnabotulinumtoxinA After Bladder Injection. Experimental Study Using the Distribution of Cleaved SNAP-25 as the Marker of the Toxin Action. European Urology, 2012, 61, 1178-1184.	1.9	72
38	Transient receptor potential vanilloid 1 mediates nerve growth factorâ€induced bladder hyperactivity and noxious input. BJU International, 2012, 110, E422-8.	2.5	27
39	813 INCREASED SYMPATHETIC ACTIVITY ENHANCES BLADDER HYPERACTIVITY AND TRIGGERS BLADDER PAIN. Journal of Urology, 2011, 185, .	0.4	0
40	1952 URINARY NEUROTROPHINS – POTENTIAL BIOMARKERS OF OVERACTIVE BLADDER. Journal of Urology, 2011, 185, .	0.4	1
41	974 AUTONOMIC SYMPATHETIC NERVOUS SYSTEM ACTIVITY IS ENHANCED DURING CHRONIC INFLAMMATION AND CONTRIBUTES TO BLADDER HYPERACTIVITY AND PAIN. European Urology Supplements, 2011, 10, 304.	0.1	0
42	Severe burn injury induces a characteristic activation of extracellular signalâ€regulated kinase 1/2 in spinal dorsal horn neurons. European Journal of Pain, 2011, 15, 683-690.	2.8	8
43	Spinal Cord Injury and Bladder Dysfunction: New Ideas about an Old Problem. Scientific World Journal, The, 2011, 11, 214-234.	2.1	54
44	Editorial [Hot Topic: An Update on Neurotrophins (Guest Editor: Celia Duarte Cruz)]. Current Neuropharmacology, 2011, 9, 522-522.	2.9	0
45	Minocycline completely reverses mechanical hyperalgesia in diabetic rats through microglia-induced changes in the expression of the potassium chloride co-transporter 2 (KCC2) at the spinal cord. Diabetes, Obesity and Metabolism, 2011, 13, 150-159.	4.4	65
46	Nerve growth factor in bladder dysfunction: Contributing factor, biomarker, and therapeutic target. Neurourology and Urodynamics, 2011, 30, 1227-1241.	1.5	115
47	Neurotrophins in the Lower Urinary Tract: Becoming of Age. Current Neuropharmacology, 2011, 9, 553-558.	2.9	16
48	Biomarkers in Overactive Bladder: A New Objective and Noninvasive Tool?. Advances in Urology, 2011, 2011, 1-7.	1.3	50
49	Distribution of the High-Affinity Binding Site and Intracellular Target of Botulinum Toxin Type A in the Human Bladder. European Urology, 2010, 57, 884-890.	1.9	89
50	Trigonal Injection of Botulinum Toxin A in Patients with Refractory Bladder Pain Syndrome/Interstitial Cystitis. European Urology, 2010, 58, 360-365.	1.9	169
51	1677 INTRA-TRIGONAL INJECTION OF BOTULINUM TOXIN A IN PATIENTS WITH REFRACTORY BLADDER PAIN SYNDROME DECREASES URINARY NEUROTROPHINS AND IMPROVES LOWER URINARY TRACT SYMPTOMS. Journal of Urology, 2010, 183, .	0.4	1
52	191 EFFECT OF BOTULINUM TOXIN TYPE A ON INTRAMURAL PARASYMPATHETIC GANGLIA OF THE GUINEA-PIG BLADDER. Journal of Urology, 2010, 183, .	0.4	2
53	85 BOTULINUM TOXIN TYPE AACTS ON BLADDER INTRAMURAL PARASYMPATHETIC GANGLIA. AN EXPERIMENTAL STUDY IN THE GUINEA-PIG. European Urology Supplements, 2010, 9, 59.	0.1	1
54	Sequestration of brain derived nerve factor by intravenous delivery of TrkB-Ig2 reduces bladder overactivity and noxious input in animals with chronic cystitis. Neuroscience, 2010, 166, 907-916.	2.3	41

CéLIA DUARTE CRUZ

#	Article	IF	CITATIONS
55	258 DISTRIBUTION AND NEUROCHEMISTRY OF BOTULINUM TOXIN TYPE A RECEPTORS IN THE URINARY BLADDER. European Journal of Pain, 2009, 13, S81b.	2.8	0
56	652 CHEMICAL NEUROMODULATION IN PATIENTS WITH BLADDER PAIN SYNDROME (BPS). European Journal of Pain, 2009, 13, S189.	2.8	0
57	653 INTRATHECAL BLOCKADE OF NGF DECREASES REFERRED PAIN IN RATS MODEL OF CHRONIC BLADDER INFLAMMATION. European Journal of Pain, 2009, 13, S189a.	2.8	0
58	654 INTRATHECAL BDNF SEQUESTRATION REDUCES REFERRED PAIN AND BLADDER OVERACTIVITY IN AN ANIMAL MODEL OF CHRONIC BLADDER INFLAMMATION. European Journal of Pain, 2009, 13, S189b.	2.8	0
59	GRC-6211, a New Oral Specific TRPV1 Antagonist, Decreases Bladder Overactivity and Noxious Bladder Input in Cystitis Animal Models. Journal of Urology, 2009, 181, 379-386.	0.4	91
60	223 DISTRIBUTION AND NEUROCHEMISTRY OF HIGH AFFINITY BINDING SITES FOR BOTULINUM TOXIN TYPE A IN THE URINARY BLADDER. European Urology Supplements, 2009, 8, 176.	0.1	4
61	603 SEQUESTRATION OF BDNF WITH A RECOMBINANT PROTEIN IMPROVES BLADDER FUNCTION IN RATS WITH CHRONIC BLADDER INFLAMMATION. European Urology Supplements, 2009, 8, 271.	0.1	0
62	HIGH AFFINITY BINDING SITES FOR BOTULINUM TOXIN TYPE A IN THE URINARY BLADDER: DISTRIBUTION AND NEUROCHEMISTRY. Journal of Urology, 2009, 181, 149-150.	0.4	0
63	Intrathecal delivery of resiniferatoxin (RTX) reduces detrusor overactivity and spinal expression of TRPV1 in spinal cord injured animals. Experimental Neurology, 2008, 214, 301-308.	4.1	32
64	THE ORAL TRPV1 ANTAGONIST GRC 6211 REDUCES BLADDER OVERACTIVITY AND NOXIOUS BLADDER INPUT IN CYSTITIS. Journal of Urology, 2008, 179, 539-539.	0.4	0
65	The activation of the ERK pathway contributes to the spinal c-fosexpression observed after noxious bladder stimulation. Somatosensory & Motor Research, 2007, 24, 15-20.	0.9	26
66	The ERK 1 and 2 Pathway in the Nervous System: From Basic Aspects to Possible Clinical Applications in Pain and Visceral Dysfunction. Current Neuropharmacology, 2007, 5, 244-252.	2.9	73
67	Increased extracellular signal regulated kinases phosphorylation in the adrenal gland in response to chronic ACTH treatment. Journal of Endocrinology, 2007, 192, 647-658.	2.6	27
68	Transient Receptor Potential Vanilloid Subfamily 1 is Essential for the Generation of Noxious Bladder Input and Bladder Overactivity in Cystitis. Journal of Urology, 2007, 177, 1537-1541.	0.4	108
69	Spinal ERK activation contributes to the regulation of bladder function in spinal cord injured rats. Experimental Neurology, 2006, 200, 66-73.	4.1	26
70	Increased spinal cord phosphorylation of extracellular signal-regulated kinases mediates micturition overactivity in rats with chronic bladder inflammation. European Journal of Neuroscience, 2005, 21, 773-781.	2.6	54
71	Inhibition of ERK phosphorylation decreases nociceptive behaviour in monoarthritic rats. Pain, 2005, 116, 411-419.	4.2	74
72	ACTH Modulates ERK Phosphorylation in the Adrenal Gland in a Timeâ€Dependent Manner. Endocrine Research, 2004, 30, 661-666.	1.2	13

#	Article	IF	CITATIONS
73	Vanilloid receptor 1 expression in the rat urinary tract. Neuroscience, 2002, 109, 787-798.	2.3	220
74	Nerve growth factor regulates galanin and c-jun overexpression occurring in dorsal root ganglion cells after intravesical resiniferatoxin application. Brain Research, 2002, 951, 264-269.	2.2	24